vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Above Fifty Day Moving Average of $21.35

vTv Therapeutics Inc. (NASDAQ:VTVT) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $21.35 and traded as high as $22.87. vTv Therapeutics shares last traded at $21.20, with a volume of 53,997 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 13th.

vTv Therapeutics Stock Up 0.9 %

The firm has a market cap of $63.81 million, a PE ratio of -2.40 and a beta of 0.65. The firm’s fifty day simple moving average is $21.35 and its two-hundred day simple moving average is $19.00.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.17) earnings per share for the quarter. The business had revenue of $1.00 million for the quarter.

Hedge Funds Weigh In On vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. Baker BROS. Advisors LP bought a new position in vTv Therapeutics Inc. (NASDAQ:VTVT) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 97,314 shares of the biotechnology company’s stock, valued at approximately $2,290,000. Baker BROS. Advisors LP owned approximately 3.23% of vTv Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.